Need professional-grade analysis? Visit stockanalysis.com
$283.40M
N/A
N/A
N/A
Silence Therapeutics plc (SLNCF) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $2.40.
Over the past year, SLNCF has traded between a low of $0.97 and a high of $2.60. The stock has gained 147.4% over this period. It is currently 7.7% below its 52-week high.
Silence Therapeutics plc has a market capitalization of $283.40M.
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Side-by-side comparison against top Healthcare peers.